| Assessment Status | Rapid Review Complete |
| HTA ID | 22053 |
| Drug | Asciminib |
| Brand | Scemblix® |
| Indication | For the treatment of Adult patients with Philadelphia chromosome positive chronic myeloid leukaemia in the chronic phase, who have previously been treated with two or more tyrosine kinase inhibitors. |
| Assessment Process | |
| Rapid review commissioned | 26/07/2022 |
| Rapid review completed | 24/08/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of asciminib compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
The HSE has approved reimbursement following confidential price negotiations. November 2023
